Table 4.
Total | Intestinal infection | Extra-intestinal infection | |||||||
---|---|---|---|---|---|---|---|---|---|
Antibiotic | Ra [n (%)] | I [n (%)] | S [n (%)] | R [n (%)] | I [n (%)] | S [n (%)] | R [n (%)] | I [n (%)] | S [n (%)] |
Ampicillinc | 108(93.9) | 3(2.6) | 4(3.5) | 92(93.9) | 2(2.0) | 4(4.1) | 16(94.1) | 1(5.9) | 0(0.0) |
Amoxicillin-clavulanatec | 15(13.0) | 76(66.1) | 24(20.9) | 8(8.2) | 68(69.4) | 22(22.4) | 7(41.2) | 8(47.1) | 2(11.8) |
Imipenemb | 3(2.6) | 10(8.7) | 102(88.7) | 2(2.0) | 7(7.1) | 88(89.8) | 1(5.9) | 3(17.6) | 14(82.4) |
Ceftriaxoneb | 17(14.8) | 3(2.6) | 95(82.6) | 5(5.1) | 3(3.1) | 90(91.8) | 12(70.6) | 0(0.0) | 5(29.4) |
Cefepimeb | 5(4.3) | 3(2.6) | 107(93.0) | 1(1.0) | 0(0.0) | 97(99.0) | 4(23.5) | 3(17.6) | 10(58.8) |
Cefoxitinb | 28(24.3) | 6(5.2) | 81(70.4) | 17(17.3) | 5(5.1) | 76(77.6) | 11(64.7) | 1(5.9) | 5(29.4) |
Gentamicinb | 6(5.2) | 4(3.5) | 105(91.3) | 2(2.0) | 2(2.0) | 94(95.9) | 4(23.5) | 2(11.8) | 11(64.7) |
Nalidixic acidc | 63(54.8) | – | 52(45.2) | 49(50.0) | 0(0.0) | 49(50.0) | 14(82.4) | 0(0.0) | 3(17.6) |
Ciprofloxacinb | 7(6.1) | 0(0.0) | 108(93.9) | 1(1.0) | 0(0.0) | 97(99.0) | 6(35.3) | 0(0.0) | 11(64.7) |
Chloramphenicolb | 10(8.7) | 2(1.7) | 103(89.6) | 8(8.2) | 2(2.0) | 88(89.8) | 2(11.8) | 0(0.0) | 15(88.2) |
Tetracyclineb | 21(18.3) | 5(4.3) | 89(77.4) | 15(15.3) | 3(3.1) | 80(81.6) | 6(35.3) | 2(11.8) | 9(52.9) |
Doxycyclinec | 4(3.5) | 4(3.5) | 107(93.0) | 2(2.0) | 2(2.0) | 94(95.9) | 2(11.8) | 2(11.8) | 13(76.5) |
Azithromycinc | 5(4.3) | – | 110(95.7) | 0(0.0) | – | 98(100.0) | 5(29.4) | – | 12(70.6) |
Trimethoprim- Sulfamethoxazoleb | 6(5.2) | – | 109(94.8) | 1(1.0) | 0(0.0) | 97(99.0) | 5(29.4) | 0(0.0) | 12(70.6) |
Sulfonamidesc | 19 (16.5) | – | 96(83.5) | 12(12.2) | 0(0.0) | 86(87.8) | 7(41.2) | 0(0.0) | 10(58.8) |
aR: Resistant; I: Intermediate; S: Sensitive
bBreakpoints are based on the CLSI M45-A3 standards for Aeromonas spp.
cOther breakpoints refer to the CLSI M100-S26E criteria for Enterobacteriaceae